PODROCK™ 25

Cefpodoxime proxetil is an oral third-generation cephalosporin prodrug. Following oral administration, it is hydrolysed by intestinal esterases to release the active cefpodoxime, which then inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) — specifically PBP1a, PBP1b, and PBP3 — blocking the transpeptidation step of peptidoglycan cross-linking.

Compared to cefixime, cefpodoxime has an extended gram-positive spectrum — it maintains reliable activity against Staphylococcus aureus (MSSA) in addition to the gram-negative coverage typical of third-generation cephalosporins (H. influenzae, M. catarrhalis, E. coli, Klebsiella, Proteus). This makes it particularly valuable for infections where staphylococcal involvement is possible alongside gram-negative pathogens — a clinical situation common in ENT, pulmonary, and skin infections.

Cefpodoxime also achieves excellent concentrations in tonsillar tissue, sinus fluid, middle ear fluid, lung parenchyma, and skin — the tissues most relevant to its primary indications. Its oral bioavailability of 50% (enhanced by food) is modestly superior to cefixime in certain infection contexts.

At 25mg per 5mL (PODROCK™ 25 Drops), this formulation is calibrated for the youngest paediatric patients — neonates above 2 months through to toddlers approximately 5–12 months (3–8 kg) — providing weight-based dosing with accurate small volumes using the graduated dropper.

PODROCK™ 25 is specifically designed for young infants requiring third-generation cephalosporin therapy with the additional advantage of MSSA coverage.

Acute Otitis Media: Primary indication in infants. Cefpodoxime achieves high middle ear fluid concentrations and covers both H. influenzae and S. pneumoniae — the two dominant causative organisms — as well as M. catarrhalis and MSSA, providing broader cover than cefixime in this age group.

Lower Respiratory Tract Infections: Bronchitis and mild community-acquired pneumonia in infants caused by susceptible H. influenzae, S. pneumoniae, and atypical pathogens (partial Mycoplasma coverage).

Pharyngitis and Tonsillitis: Group A Streptococcal pharyngitis — cefpodoxime achieves excellent tonsillar tissue concentrations with a reliable streptococcal eradication rate.

Urinary Tract Infections: E. coli and Klebsiella UTIs in infants — high urinary drug concentrations ensure reliable bacteriuria eradication.

Skin Infections: Mild impetigo and superficial cellulitis caused by MSSA and Streptococcus pyogenes in infants — the MSSA coverage of cefpodoxime is a significant advantage over cefixime in dermatological infections.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.